CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
The closing of the Offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be ...
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock ...